title: Comparison of the selectivity of anti-varicella-zoster virus nucleoside analogues.
abstract: We compared the selectivity of six anti-varicella-zoster virus (VZV) drugs, which are clinically available or of which clinical efficacy for the treatment of VZV infections has been reported. Sorivudine (BV-araU) had the most potent anti-VZV effect in the plaque inhibition assay, followed by brivudine (BVDU) and 5-propynyl-arabinofuranosyluracil (Pry-araU). All test compounds, except vidarabine (AraA), had only a very weak effect on human embryonic lung cell growth. The selectivity indexes (ID50 for cell growth/ED50 for VZV plaque inhibition) of BV-araU, BVDU, and Pry-araU were > 1,000,000, 20,000, and > 10,000, respectively, while those of acyclovir and penciclovir ranged from 600 to 800. AraA was much less selective than any of the other drugs tested. We measured the amount of [3H] thymidine incorporated into the acid-insoluble fraction of VZV-infected cells to determine the ability of these drugs to selectively inhibit viral DNA synthesis. [3H]Thymidine incorporation was markedly inhibited by all anti-VZV compounds, except BVDU. Treatment of infected cells with drugs from 32 to 38 hr after infection inhibited the DNA synthesis to the same extent as VZV plaque formation, except that AraA inhibited the DNA synthesis at a lower dose than for VZV plaque formation. DNA synthesis in non-infected growing cells was inhibited to the same extent as cell growth. A particularly high selectivity index for the inhibition of DNA synthesis was noted for BV-araU, which was defined as the ratio of inhibitions of DNA synthesis in VZV-infected and non-infected. The highest selectivity indexes were recorded for BV-araU > Pry-araU > acyclovir > or = penciclovir > AraA.
authors.affiliation: Biology Laboratory, Yamasa Corp., Chiba, Japan.
authors.forename: H
authors.initials: H
authors.lastname: Machida
authors.forename: M
authors.initials: M
authors.lastname: Nishitani
authors.forename: Y
authors.initials: Y
authors.lastname: Watanabe
authors.forename: Y
authors.initials: Y
authors.lastname: Yoshimura
authors.forename: F
authors.initials: F
authors.lastname: Kano
authors.forename: S
authors.initials: S
authors.lastname: Sakata
mesh_terms: D000998:Antiviral Agents / Q000737:chemistry / Q000494:pharmacology*; D002455:Cell Division / Q000187:drug effects; D002460:Cell Line; D002478:Cells, Cultured; D004247:DNA / Q000096:biosynthesis; D004261:DNA Replication / Q000187:drug effects; D004279:DNA, Viral / Q000096:biosynthesis / Q000187:drug effects; D014645:Herpesvirus 3, Human / Q000187:drug effects* / Q000235:genetics / Q000254:growth & development; D006801:Humans; D008168:Lung / Q000821:virology; D009705:Nucleosides / Q000737:chemistry / Q000494:pharmacology*; D013329:Structure-Activity Relationship; D013936:Thymidine; D010948:Viral Plaque Assay
chemical_list: D000998:Antiviral Agents; D004279:DNA, Viral; D009705:Nucleosides; D004247:DNA; D013936:Thymidine